Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Direct-acting antiviral-based therapy for chronic hepatitis C virus in HIV-infected patients

Direct-acting antiviral-based therapy for chronic hepatitis C virus in HIV-infected patients Downloaded from http://journals.lww.com/co-hivandaids by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/02/2020 REVIEW URRENT Direct-acting antiviral-based therapy for chronic PINION hepatitis C virus in HIV-infected patients a a a a David Del Bello , Fanny Ita Nagy , Jonathan Hand , Rabea Khedemi b a,c b Julien Le´cluse-Barth , Douglas Dieterich , and Lionel Piroth Purpose of review The aim of this review was to detail the current therapies and treatments for chronic hepatitis C virus in coinfected patients, focusing on HCV antiviral agents currently used in practice today or scheduled to enter the open market soon. Recent findings Several direct-acting antiviral (DAA) combinations show high sustained virologic response (SVR) rates in HIV/HCV-coinfected patients, which are often close to those observed in HCV-monoinfected patients. Most recommendations regarding treatment stem from trials with coinfected patients. However, data are lacking for some aspects of HCV-treatment in coinfection, so extrapolations must be made from data obtained predominately from monoinfected patients. Summary HIV/HCV-coinfected patients, who, not too long ago, had inferior outcomes in capturing SVR, now enjoy similar fates as the monoinfected patients. They should thus be prioritized for treatment, since HCV and liver disease have become major causes of morbidity and mortality in this population. However, potential http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV & AIDS Wolters Kluwer Health

Direct-acting antiviral-based therapy for chronic hepatitis C virus in HIV-infected patients

Download PDF
11 pages

Loading next page...
 
/lp/wolters-kluwer-health/direct-acting-antiviral-based-therapy-for-chronic-hepatitis-c-virus-in-HvXt2NRJ7O

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0000000000000182
Publisher site
See Article on Publisher Site

Abstract

Downloaded from http://journals.lww.com/co-hivandaids by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/02/2020 REVIEW URRENT Direct-acting antiviral-based therapy for chronic PINION hepatitis C virus in HIV-infected patients a a a a David Del Bello , Fanny Ita Nagy , Jonathan Hand , Rabea Khedemi b a,c b Julien Le´cluse-Barth , Douglas Dieterich , and Lionel Piroth Purpose of review The aim of this review was to detail the current therapies and treatments for chronic hepatitis C virus in coinfected patients, focusing on HCV antiviral agents currently used in practice today or scheduled to enter the open market soon. Recent findings Several direct-acting antiviral (DAA) combinations show high sustained virologic response (SVR) rates in HIV/HCV-coinfected patients, which are often close to those observed in HCV-monoinfected patients. Most recommendations regarding treatment stem from trials with coinfected patients. However, data are lacking for some aspects of HCV-treatment in coinfection, so extrapolations must be made from data obtained predominately from monoinfected patients. Summary HIV/HCV-coinfected patients, who, not too long ago, had inferior outcomes in capturing SVR, now enjoy similar fates as the monoinfected patients. They should thus be prioritized for treatment, since HCV and liver disease have become major causes of morbidity and mortality in this population. However, potential

Journal

Current Opinion in HIV & AIDS – Wolters Kluwer Health

Published: Sep 1, 2015

There are no references for this article.